Retatrutide is an investigational triple agonist that activates GLP-1, GIP, and glucagon receptors. Adding glucagon agonism is counterintuitive at first — glucagon is best known for raising blood sugar — but in this receptor context it appears to increase energy expenditure and promote hepatic fat loss without offsetting the insulin-sensitizing effects of GLP-1 and GIP.
What the Phase 2 data showed
Why the triple mechanism is interesting
Glucagon receptor agonism activates hepatic fat oxidation and increases resting energy expenditure. GLP-1 and GIP together maintain glucose control and appetite suppression. In principle this combination targets both sides of the energy balance equation — intake and expenditure — from within a single molecule.
What we still do not know
- Long-term safety beyond current trial durations
- Cardiovascular outcome data
- How weight loss is maintained after discontinuation
- Body-composition effects (fat vs lean mass) in independent research
- How real-world adherence compares to trial conditions
“Retatrutide is exciting research. It is not a personal recommendation. My job is to help clients think clearly about what is established, what is emerging, and what is still hypothesis — and to keep the fundamentals in place regardless of which molecule the future settles on.”
“I read this research the same way I read any new class of therapy: interested, patient, and skeptical of hype in either direction. Big numbers in phase 2 trials often shrink at phase 3 and shrink again in the real world. Whatever the next generation of metabolic drugs ends up looking like, the coaching principles do not change. Muscle mass matters. Sleep matters. Protein matters. The molecule is downstream of the person.”
References
- Jastreboff AM, et al.. Triple–Hormone-Receptor Agonist Retatrutide for Obesity. N Engl J Med. 2023. doi:10.1056/NEJMoa2301972
- Rosenstock J, et al.. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. The Lancet. 2023. doi:10.1016/S0140-6736(23)01053-X
Related reading
8 min · Beginner
GLP-1 Fundamentals: How the Hormone Actually Works
GLP-1 is a naturally occurring gut hormone that quietly coordinates appetite, insulin release, and how quickly your stomach empties. Understanding it is the foundation for every conversation about modern metabolic therapies.
8 min · Intermediate
Tirzepatide: Dual GIP/GLP-1 Agonism Explained
Tirzepatide simultaneously activates GLP-1 and GIP receptors. That dual signal appears to produce larger metabolic effects than GLP-1 alone — but with the same lifestyle rules attached.
6 min · Intermediate
Dual and Triple Agonists: The Direction Metabolic Medicine Is Heading
The next wave of metabolic drugs stacks receptor signals. Understanding why helps you interpret the pipeline rationally instead of by headline.
Apply this
Turn this education into a personalized plan.
Everything on this page is general education. The real leverage comes from applying it to your history, goals, and lifestyle. Start with our Health Assessment.